Defining hematoma expansion in intracerebral hemorrhage Relationship with patient outcomes
D Dowlatshahi, AM Demchuk, ML Flaherty, M Ali, PL Lyden, EE Smith
Neurology | LIPPINCOTT WILLIAMS & WILKINS | Published : 2011
Awarded by Chief Scientist Office
Dr. Dowlatshahi was supported by a Canadian Institutes of Health Research Fellowship award and a University of Ottawa Fellowship for New Faculty award. Dr. Demchuk has served on a scientific advisory board for Boehringer Ingelheim; has received funding for travel and speaker honoraria from Boehringer Ingelheim and Sanofi-Aventis; serves on the editorial boards of Journal of Neuroimaging, Stroke, and the International Journal of Stroke; and receives research support from Novo Nordisk and the NIH/NINDS. Dr. Flaherty has served as a consultant for Boehringer Ingelheim and receives research support from Novo Nordisk and the NIH/NINDS. Dr. Ali reports no disclosures. Dr. Lyden serves on a scientific advisory board for CoAxia, Inc.; has received funding for travel from Mitsubishi Tanabe Pharma Corporation and PhotoThera; serves on the editorial boards of Stroke, International Journal of Stroke, and Journal of Stroke and Cerebrovascular Disorders; receives publishing royalties for Thrombolytic Therapy for Acute Ischemic Stroke, 2<SUP>nd</SUP> ed. (Humana Press, 2006); serves as a consultant for Mitsubishi Tanabe Pharma Corporation, BeneChill, Inc., PhotoThera, CoAxia, Inc., Pfizer Inc., and ZZ Biotech L. L. C.; and has received research support from the NIH and the US Veterans Administration. Dr. Smith has served on a scientific advisory board for Genentech, Inc.; received speaker honoraria from the Canadian Conference on Dementia; serves as an Assistant Editor for Stroke; has served on speakers' bureaus for QuantiaMD and BMJ Best Practice; and receives research support from the NIH/NINDS, Canadian Institutes for Health Research, Canadian Stroke Network, a the Alberta Heritage Fund for Medical Research, and Hotchkiss Brain Institute.